Oncology
Tumor
3
Pipeline Programs↗
19
Active Trials↗
18
Companies Involved↗
Tumor is an early-stage landscape with 3 programs across 18 companies. The most active players are Obsidian Therapeutics, Inc., Genmab, Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Monoclonal antibody150%
Modality classified for 60% of 5 pipeline programs.
Analysis
Trial Status
58
clinical trials
Completed20 · 34%
Recruiting12 · 21%
Unknown status10 · 17%
Not yet recruiting7 · 12%
Terminated6 · 10%
Withdrawn3 · 5%
Clinical Trials
Trial Activity
58 trials
Fluorescent Intra-operative Tumor Margin Examination
Recruiting·—·Phase 2·NCT04719156·110 enrolled
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT04770207·100 enrolled
A Natural History Study of Bone and Mineral Disorders
Recruiting·National Institute of Dental and Craniofacial Research (NIDCR)·N/A·NCT00024804·1,000 enrolled
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
Not yet recruiting·—·Phase 2·NCT07312292·15 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)